drugset / Trial / NCT01431404
Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 liquid with those of etanercept (enbrel) prefilled injection after subcutaneous injection.
Timeline
- Start
- 2011-08
- Primary completion
- 2012-03
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etanercept | Protein / enzyme biologic | 25 mg | Subcutaneous |
| Subject | HD203 | Unknown | 25 mg | Subcutaneous |
Indications
No indication recorded.